Tirzepatide 15mg High-Purity Research Peptide

Tirzepatide 15mg High-Purity Research Peptide — Comprehensive Product Overview Tirzepatide 15 mg is a premium research-grade dual GIP/GLP-1 receptor agonist peptide designed for laboratories requiring the mid-range material quantity ideal for receptor binding kinetics studies, competitive displacement assays, and comprehensive pharmacological profiling. The 15 mg dosage represents an optimal sweet spot for researchers who need more material than entry-level vials provide but prefer the experimental flexibility of a moderate quantity that can be consumed within a focused study timeline. Tirzepatide (CAS: 2023788-19-2, MW: 4813.5 Da) is a 39-amino acid synthetic peptide amide engineered to deliver balanced, potent co-agonism at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). The peptide sequence — H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-γ-Glu-eicosanedioic acid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 — features the same molecular architecture as other Tirzepatide dosages, with Aib residues at positions 2 and 13 providing DPP-4 resistance and helical stabilization, and the C20 fatty diacid moiety at Lys20 delivering extended pharmacokinetic duration through high-affinity reversible albumin binding. What distinguishes the 15 mg format is its research utility for receptor pharmacology: this quantity provides sufficient material for comprehensive radioligand binding saturation and competition experiments (determining Kd, Bmax, and Ki values), full cAMP dose-response curves with 10-12 concentration points in triplicate, β-arrestin recruitment profiling, and parallel signaling pathway analysis (Gαs, Gαq, and β-arrestin-2 pathways) — all from a single vial. The ≥99% HPLC purity specification is rigorously enforced through batch-level analytical testing, ensuring that receptor binding and signaling data are uncontaminated by peptide-related impurities that could confound pharmacological interpretations. Each vial is manufactured under GMP-aligned quality systems with full raw material traceability and batch-specific analytical documentation. Supplied strictly for research use only (RUO), this product is not intended for human or veterinary diagnostic, therapeutic, clinical, or prophylactic use. Key Features 15 mg high-purity research vial — the mid-range quantity optimized for comprehensive receptor pharmacology studies and binding kinetics experiments Dual GIP and GLP-1 receptor agonist — the synergistic dual mechanism that defines Tirzepatide’s unique pharmacological profile ≥99% HPLC-verified purity — every batch tested with full chromatogram and mass spectrometry documentation Lyophilized powder for maximum stability — shelf life of 24+ months at -20°C under desiccated storage conditions DPP-4-resistant design — Aib residues at positions 2 and 13 prevent enzymatic degradation by the primary incretin-cleaving protease Albumin-binding pharmacokinetic extension — C20 diacid moiety enables reversible HSA binding for prolonged receptor engagement in research models Complete analytical package — HPLC purity, ESI-MS molecular weight confirmation, AAA compositional analysis, and endotoxin testing data Ideal for receptor binding, signaling bias, competitive displacement, and pharmacological profiling studies The Science of Tirzepatide: Dual GIP/GLP-1 Receptor Pharmacology Tirzepatide’s mechanism of action represents a sophisticated example of biased polypharmacology — a single molecular entity engaging two distinct G protein-coupled receptors (GPCRs) with differential potency and signaling bias. At the GIP receptor, Tirzepatide functions as a super-agonist, exhibiting approximately 5-fold greater cAMP accumulation potency compared to native GIP. This enhanced GIPR activity is believed to contribute to improved β-cell function, enhanced insulin secretory capacity, and beneficial effects on adipose tissue metabolism including increased lipid storage capacity and reduced ectopic lipid deposition. At the GLP-1 receptor, Tirzepatide acts as a balanced full agonist with potency comparable to native GLP-1, engaging the canonical Gαs-cAMP-PKA signaling axis to stimulate glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and activate hypothalamic satiety circuits. The molecular basis for Tirzepatide’s imbalanced dual agonism lies in its structural derivation from the native GIP sequence. Computational modeling and cryo-EM structural studies have revealed that Tirzepatide’s GIPR binding mode closely resembles that of native GIP, with extensive contacts between the peptide’s C-terminal helix and the receptor’s extracellular domain, while GLP-1R binding involves a distinct set of interactions that permit activation despite the peptide’s primary sequence being optimized for GIPR engagement. The 15 mg vial provides researchers with sufficient material to systematically probe these receptor interactions using mutagenesis studies, chimeric receptor constructs, and domain-swapping experiments that map the structural determinants of dual receptor recognition. The synergistic effects of dual receptor activation are particularly evident in insulin secretion assays. In isolated islet preparations, the combination of GIPR and GLP-1R agonism produces insulin secretory responses that exceed the additive sum of individual receptor activation — a phenomenon known as supra-additivity or synergy. This synergy arises from the convergence of GIPR and GLP-1R signaling at multiple nodes: both receptors couple to Gαs and elevate cAMP, but GLP-1R additionally engages Gαq-mediated calcium mobilization and the EPAC2-dependent amplification pathway, while GIPR provides a sustained cAMP signal that potentiates both PKA and EPAC2 effectors. Research Applications Tirzepatide 15 mg is optimized for the following research applications: Receptor binding kinetics and saturation binding studies — using radiolabeled (³H, ¹²⁵I) or fluorescently tagged Tirzepatide to determine equilibrium dissociation constants (Kd), maximum binding capacity (Bmax), and kinetic rate parameters (kon, koff) at recombinant and endogenous GIPR and GLP-1R; Competitive displacement (competition binding) assays — measuring Tirzepatide’s ability to displace radiolabeled native ligands (¹²⁵I-GIP, ¹²⁵I-GLP-1) to determine Ki values and assess competitive vs. allosteric binding modes; Signaling bias and functional selectivity profiling — quantitative comparison of G-protein (cAMP, IP1, calcium) vs. β-arrestin (BRET, enzyme complementation) signaling outputs to calculate bias factors (Δlog(τ/KA), ΔΔlog(τ/KA)) at both receptor subtypes; Receptor mutagenesis and structure-function studies — alanine-scanning mutagenesis, chimeric receptor constructs, and domain-swapping experiments to identify critical receptor residues and domains mediating dual agonist recognition; Concentration-response pharmacology — full 10-12 point concentration-response curves for cAMP, pCREB, pERK, β-arrestin recruitment, insulin secretion, and other functional endpoints; Head-to-head comparator studies — systematic comparison of Tirzepatide, Semaglutide, native GIP, native GLP-1, oxyntomodulin, and other incretin peptides across identical assay platforms; Islet perifusion studies — dynamic insulin secretion profiling using perifused isolated islets to assess temporal patterns of insulin release in response to pulsatile Tirzepatide exposure. Comparative Analysis: Tirzepatide vs. Semaglutide vs. Retatrutide The choice between Tirzepatide, Semaglutide, and Retatrutide depends on the specific research question: Semaglutide (GLP-1R-selective) provides a clean, single-target pharmacological tool for GLP-1 biology studies. It serves as an essential control compound when researchers need to attribute metabolic effects specifically to GLP-1R activation. However, Semaglutide cannot capture the GIPR-mediated contributions to β-cell function, adipose tissue metabolism, and synergistic insulin secretion that are central to Tirzepatide pharmacology. In comparative binding and signaling studies, Semaglutide is inactive at GIPR at all tested concentrations, confirming its selectivity and reinforcing the unique dual-receptor profile of Tirzepatide. Tirzepatide (dual GIP/GLP-1R) offers the cleanest window into GIP-GLP-1 synergy without the added complexity of glucagon receptor (GCGR) engagement. This intermediate pharmacological complexity makes Tirzepatide the preferred tool for researchers investigating the specific contributions of GIPR agonism in the presence of GLP-1R co-activation. The 15 mg vial size is particularly advantageous for binding and signaling assays because it enables the most comprehensive pharmacological characterization — Kd, Ki, EC50, Emax, bias factors, and kinetic rate constants for both receptor subtypes — from a single vial. Retatrutide (GIP/GLP-1R/GCGR triple agonist) adds glucagon-mediated metabolic effects including increased energy expenditure, hepatic fatty acid oxidation, and amino acid catabolism. While scientifically fascinating, the GCGR component introduces variables (hepatic glucose output, nitrogen balance, adrenal effects) that may confound studies focused on GIP biology. For researchers whose primary interest lies in the GIP-GLP-1 axis, Tirzepatide’s dual mechanism provides cleaner data with fewer confounding variables. The 15 mg Tirzepatide vial supports statistically powered head-to-head comparisons across all three peptides, enabling comprehensive characterization of the incretin pharmacological landscape. Disclaimer This product is intended exclusively for laboratory research purposes only. It is not approved by the FDA or any other regulatory authority for human or veterinary diagnostic, therapeutic, clinical, or prophylactic use. Purchasers must be qualified researchers affiliated with recognized laboratories, universities, biotechnology companies, or research institutions. By purchasing this product, the buyer acknowledges and agrees to use it solely for legitimate scientific research in compliance with all applicable laws, regulations, and institutional guidelines. Product Specifications Product Name: Tirzepatide CAS Number: 2023788-19-2 Molecular Formula: C225H348N48O68 Molecular Weight: 4813.5 Da Sequence: H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-γ-Glu-eicosanedioic acid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 Purity: ≥99% (HPLC, 214 nm) Strength: 15 mg per vial Form: Sterile lyophilized powder Grade: Research Use Only (RUO) Solubility: Soluble in aqueous buffers (PBS, pH 7.4) and organic solvents (DMSO, DMF) for research Storage: Store lyophilized powder at -20°C; after reconstitution, store aliquots at -20°C or -80°C; avoid repeated freeze-thaw cycles Quality Assurance & Analytical Testing Our Tirzepatide 15 mg undergoes rigorous multi-method analytical characterization: HPLC Purity (214 nm) — ≥99% main peak purity with full chromatogram documentation; ESI Mass Spectrometry — molecular weight confirmation within ±1.0 Da of theoretical 4813.5 Da; Amino Acid Analysis — compositional verification of correct amino acid ratios and identification of Aib residues; Peptide Content — nitrogen determination or quantitative amino acid analysis for accurate peptide mass per vial; Endotoxin Testing (LAL Kinetic Chromogenic) — endotoxin quantification for cell-based and in vivo research suitability; Residual Solvents (GC-HS) — verification per ICH Q3C guidelines; Appearance, Solubility, and pH — confirming proper physical characteristics; Batch-specific CoA available upon request with complete analytical data package. Handling & Storage Guidelines Lyophilized Tirzepatide 15 mg: store at -20°C in desiccated conditions; stable for 24+ months; Reconstitution: for research use, add 1.5-15 mL sterile PBS (pH 7.4) or 0.1% acetic acid to achieve desired stock concentration (1-10 mg/mL); vortex gently to dissolve; avoid vigorous agitation; Post-reconstitution storage: aliquot into single-use volumes and store at -20°C (short-term, up to 4 weeks) or -80°C (long-term, up to 6 months); avoid freeze-thaw cycles; Working solution stability: ≥95% bioactivity maintained for 7 days at 4°C in PBS (pH 7.4); prepare working dilutions fresh daily; Handling precautions: use aseptic technique; work in biosafety cabinet; wear PPE including gloves and lab coat; ensure sterility of all solvents and glassware. USA Shipping & Availability Fast USA domestic shipping — 1-2 business day order processing from US fulfillment centers; Temperature-monitored shipping with insulated cold-chain packaging; Secure, discreet laboratory packaging; Available to qualified laboratories, universities, biotech companies, and research institutions across the USA; International shipping to select countries for qualified institutions — contact for country-specific policies; Volume and wholesale pricing available for institutional research programs — contact our scientific sales team. Why Choose Our Tirzepatide 15 mg? Optimal research quantity for comprehensive receptor pharmacology studies — binding kinetics, competitive displacement, signaling bias, and structure-function analyses from a single vial; ≥99% HPLC purity with complete analytical traceability — essential for publication-quality binding and signaling data; Dual GIP/GLP-1 receptor agonist enabling investigation of synergistic incretin biology; Full molecular characterization — CAS number, sequence with modification details, MW verification, and purity documentation; Batch-specific quality data — CoA with HPLC chromatograms, mass spectra, and amino acid analysis available upon request; Trusted supplier to academic, pharmaceutical, and biotechnology researchers across the United States; Competitive pricing with institutional discounts and bulk order options. Advantages and Limitations Advantages: 15 mg quantity ideal for comprehensive binding, signaling, and pharmacological profiling studies; Dual-receptor agonism enables investigation of synergistic GIP-GLP-1 biology inaccessible to single-receptor agonists; ≥99% HPLC purity ensures binding and signaling data reflect Tirzepatide activity, not impurities; Sufficient material for full receptor pharmacology characterization (Kd, Ki, EC50, bias factors) from a single vial; Rigorous batch testing supports publication-quality research and regulatory documentation. Limitations: Not approved for clinical, diagnostic, or therapeutic use in humans or animals; Requires proper laboratory handling, aseptic technique, and cold storage; For extended in vivo chronic dosing studies, consider 30 mg, 50 mg, or 60 mg formats; Bioactivity validation required in each laboratory’s specific experimental system. Frequently Asked Questions (FAQs) Q: Is Tirzepatide 15 mg FDA-approved? A: No. This product is exclusively for laboratory research and is not approved for human or veterinary clinical use. Q: Who can purchase this product? A: Qualified researchers affiliated with laboratories, universities, biotechnology companies, and accredited research institutions. Q: Do you ship within the USA? A: Yes, fast domestic shipping from US-based fulfillment centers. Q: What analytical data is provided? A: Product information sheet included; batch-specific CoA with HPLC, MS, and AAA data available upon request. Q: How should I store Tirzepatide 15 mg? A: Lyophilized: -20°C (24+ months). Reconstituted: aliquot and store at -20°C or -80°C; avoid freeze-thaw. Q: What is the purity specification? A: ≥99% by HPLC at 214 nm — verified for every production batch. Q: How does Tirzepatide compare to Semaglutide? A: Tirzepatide is a dual GIP/GLP-1 agonist; Semaglutide is GLP-1R-selective only. The dual mechanism produces synergistic metabolic effects. Q: Is this suitable for binding assays? A: Yes, the 15 mg quantity and ≥99% purity make it ideal for radioligand binding, SPR, and related receptor pharmacology studies. Q: Do you offer bulk pricing? A: Yes, contact our sales team for institutional volume pricing. Q: What is the shelf life? A: 24+ months when stored lyophilized at -20°C in desiccated conditions. Ordering Information Order Tirzepatide 15 mg at hkpeptidesworldwide.com. We accept institutional purchase orders, credit cards, and wire transfers. For technical questions, bulk inquiries, or custom peptide projects, contact our scientific sales team. HK Peptides Worldwide — your trusted source for high-purity research peptides in the USA.

Related Research & Resources

Resource	Description
Glp 1 Metabolic Peptides Hub	Complete research overview & methodology hub
High Purity Tirzepatide 50Mg	Related research peptide product
Tirzepatide 10 Mg Research Peptide Vials	Related research peptide product
Glp 1 Peptides Metabolic Research	Latest research insights & methodology

View Complete Research Guide »